HRTX — Heron Therapeutics Share News
0.000.00%
Last trade - 00:00- $57.49m
- $158.52m
- $154.90m
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Heron Therapeutics Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: U.S. District Court Issues Decision Regarding CINVANTI Patents
Heron Therapeutics' Q1 revenue falls as oncology sales drop
Heron Therapeutics Q4 revenue dips as Acute Care segment holds fort
Brief: Heron Therapeutics Announces Preliminary, Unaudited Q4 Results
Brief: Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)
Heron Therapeutics posts higher Q3 revenue, backs FY forecasts
Brief: Heron Therapeutics Files For Mixed Shelf Of Up To $125 Million - SEC Filing
Heron Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Heron Therapeutics Inc expected to post a loss of 1 cent a share - Earnings Preview
Heron Therapeutics Q2 revenue rises 3.3%, raises EBITDA guidance
Brief: Heron Therapeutics Announces Q2 2025 Financial Results And Highlights Commercial Progress
Heron Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Heron Therapeutics Announces Settlement With Mylan Related To Cinvanti® And Aponvie® Patent Litigations
Heron Therapeutics Inc expected to post a loss of 1 cent a share - Earnings Preview
Heron Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Heron Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Heron Therapeutics Amends Working Capital Facility Agreement